Login to Your Account


FINANCINGS NEWS
Financings Roundup
Tokai Adds $35.5M in Series E, Preps for Phase III CRPC Trials
Development of Tokai Pharmaceuticals Inc.'s triple-acting prostate cancer drug galeterone got a $35.5 million boost, with the Cambridge, Mass.-based biotech closing a Series E round with current investors Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors.
READ MORE »
Financings Roundup
Beyond Kalbitor: Dyax Adds $30M for HAE Prophylactic
Dyax Corp. is more than doubling its cash position with a $30 million registered direct offering, with proceeds to fund R&D activities, namely clinical development of DX-2930, a drug slated to start clinical development for prophylactic use in hereditary angioedema (HAE).
READ MORE »
Financings Roundup
Receptos Prices Solid IPO, Raises $72.8M for Pipeline
Receptos Inc., of San Diego, priced its initial public offering (IPO) of 5.2 million shares of common stock at $14 per share, for a total raise of $72.8 million. The stock began trading on Nasdaq under the symbol "RCPT" Thursday, closing at $14.
READ MORE »
More FINANCINGS Headlines
Arrowhead Bolsters Balance Sheet, Adds $36M for Pipeline »
Extending the Runway: $54M Cash Infusion for Symphogen »
Capital Royalty's $805M Fund: Sifting Through Surplus of Deals »
Phase III-Ready Anticoagulant Awaits Cash from Regado IPO »
Opsona's TLR Biology Will Get a $43M Shot in the Arm »
Epizyme Files for IPO, Aims for $69M for Epigenetics Platform »
GW Sets Terms for U.S. IPO; $40M for Cannabinoid Drugs »
Durata Pads Coffers Ahead of NDA; Kamada Files for U.S. IPO »
Synergy Offering to Bring in $90M for GI Drug Development »
MedDay Raises $10.5M for Neurological Drug R&D »
IPO Flurry Continues: Receptos Files Proposed $86M Offering »
Vernal Aquinox: Series C Gets $18M to Finish Phase II Trials »
Revance Adds $33M for BoNTA Alternative to Botox »
Chimerix, Omthera Set Terms; IPO Lipidity Liquidity Ahead? »
Vivus Plays for Time; Enters $110M Capped Royalty Deal »
Enanta Raises $56M in IPO; Soars on First Day Trading »
Antibiotic Developer Tetraphase Prices Initial Public Offering »
Elite Pairing with VC Opens China to West »
Progenitor Labs Raises $5.8M for Adult Stem Cell Work »
Following Ravicti Win in UCD, Hyperion Seeks $59.7M for HE »
Prior to Commercialization, Pharmacyclics Brings in $270M »
Regenerative Medicine Specialist Mesoblast Lands $174.6M »
Ablynx Pads Cash Reserves to Push RA Drug into Phase IIb »
$7M Series B Puts Investor Skin in Game for Brickell »
Immunomedics Seeks $14M as Bridge to Milestones »
Tesaro Turns to Public Markets for Next 12 Months' Cash »
Cash-Healthy Achillion Plans to Raise $125M Via Offering »
Oncolytics Stock Offering Gets $32M to Push Reolysin »
On Brink of Phase III, Sophiris Files IPO to Advance BPH Bid »
Tygacil by the Tail? Tetraphase IPO: $86M for New Antibiotics »
e-Therapeutics Raises $63M to Fund Solid Tumor Drug »
Medgenics Lays More Runway for Biopump with $30M Raise »
Celldex Seeks $90M, End Zone for Rindopepimut »
Newlink Adds $42.5M in Public Offering for Immunotherapies »
Stemline Therapeutics Is First Biotech IPO of 2013 »
Bone Therapeutics Gets $10M For Cell Therapy Development »
Anthera Approaches Phase III, Prices $40M Public Offering »
Enbrel Drives Amgen Earnings; Company Shoots High for Year »
Gene Signal Raises New Cash for Its Antisense Drug Trials »
MolMed Adding $6.5M Ahead of Key Program Milestones »
Aiming for NDA, Trius Pads Coffers with $30M Offering »
Theravance's $250M in Notes to Pay GSK LABA Milestones »
Back in 'Control': Tivo Data Explained; AVEO Bags $50M »
Calling Interference: Alnylam Stock Offering Garners $150M »
Onyx Public Offering Will Beef Up Kyprolis Marketing Push »
Versartis' $25M Series C to Fund HGH Trial in Children »
Aileron $12M Raise to Propel Stapled Peptide into Clinic »
ISA Moving HPV Vaccine into Phase II with $10.5M Round »
Solstice Closes $18M Series A; Raises Stakes in RNAi Delivery »
FANG Bites Off $24M Series B; Gradalis Ovarian Trial Advance »
Poxel Adds $17M in Series B For Diabetes Drug Imeglimin »
HC Royalty Inks Hefty Deals to Propel Nuron and Raptor »
Blend Gets $16M in Series B; Brewing Platinum Nano-Drug »
Cytori Fattens Coffers: $18.5M for Adipose Stem Cell Efforts »
To 'Infinity' and Beyond: $150M to Propel PI3K Inhibitor IPI-145 »
Sofinnova Closes $312M 7th Fund; Bets on Life Sciences »
Derma Sciences Enters Home Stretch with $29.3M Funding »
Zafgen $21M Raise to Move Beloranib Beyond Phase IIa »
Flexion Adds $20M in Series B on Newly Focused OA Pipeline »
Rib-X Skips IPO, Opts for $67.5M Equity Financing »
Arno Advances Cancer Pipeline with $12.7M Private Placement »
TxCell Lands $16M to Advance Immunotherapy for Crohn's »
Is Tau How? GMS Bets $31.5M on Alzheimer's Phase III Effort »
Complix's Series B to Move Alphabodies into the Clinic »
Set for Late-Stage Transition, Array Pads Coffers with $66M »
FLT3 Bid 'Astellas' Promising as Before: Ambit Raises $50M »
MEI Pharma to Advance HDAC Inhibitor with $27.5M Raise »
'Cysteine' Chapel, Holy Grail? Principia Funding Nets $12.5M »
No Bones About It: $35M Add Helps Drive Thrasos' AKI Drug »
Bringing RNA Back, Mirna Gets $34.5M in Series C »
Addex Strengthens Balance Sheet with $10M Placement »
Spanish Firm Genmedica Adds $15M for Type II Diabetes Trial »
'Gates' Swing Open to $30M in Genocea Series C Funding »
Ear, Ear: Fibrocell Placement Adds $45M to Boost LaViv »
Ardelyx, AstraZeneca Sign $272M NHE3 Inhibitor Deal »
Antibody Firm KaloBios Enters IPO Queue, Aims to Raise $60M »
VC Investments Pick Up Pace; Heartening Number of Series A »
Insmed Prices $26M Offering Focusing on CF lung infections »
KaloBios Adds $35M in Debt, Equity for Asthma, CF Trials »
F2G's $30M Round to Support New F3 Antifungal Program »
MAP Seeks $52M, Prepares to Resubmit Levadex NDA »
Relypsa Loads $80M Series C to Fund Patiromer Phase III »
Investors Get Bullish on ADCs; Mersana Closes $27M Round »
Hyperion Lowers Price, Adds Shares in $50M IPO »
Bluebird Soaring with $60M Series D for Gene Therapy »
Histogenics $49M Round to Advance NeoCart Implant »
Investors Step Up for PTC's $30M Round for DMD Trials »
Cell Medica Adds $26.5M via Public, Private Funding Round »
Anthera Raises $33M After Stock Bump on Lupus Data »
Durata Completes $68M IPO; Prices Below Target Range »
Juventas Preps for Phase II Studies with $22M Series B »
RedX Pharma Raising $17M for Antiviral, Antibody Work »
Synageva Rides Stock Crest, Seeks $100M Public Offering »
PsiOxus Lands $34M to Create 4 Years of Runway for ColoAd1 »
Genkyotex Pulls in $26M to Advance Its NOX Inhibitor »
MediGene Pads Coffers, Inks $17.7M Eligard Royalty Deal »

Cast Your Vote

What is biopharma’s biggest need on the regulatory front?:

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Privacy Policy | Terms of Use
 
Part of Thompson Media Group LLC

Free Ezine

Sign up for Perspectives FREE e-mail newsletter.

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.